Uploaded November 2025 | Updated September 2026, 3 days ago

---

Could a small oral pill transform obesity and type 2 diabetes care? Discover the groundbreaking ATTAIN trial, presented at EASD 2025, which tested a novel small-molecule GLP-1 receptor agonist - ORFORGLIPRON - in over 3,000 participants.

Prof. Sean Wharton (University of Toronto & Wharton Medical Clinic) and Prof. Nasreen Alfaris (King Fahad Medical City) explain how this oral therapy achieved meaningful weight loss, improved cardio-metabolic markers, and offers a scalable solution for diabetes prevention. Learn why this easily adminstered drug could change the way clinicians worldwide approach obesity and early type 2 diabetes intervention.

Follow EASD TV for more cutting edge research updates from the world's leading experts.